Evaluation of a differential radioimmunoassay technique for the determination of morphine and morphine-6-glucuronide in human plasma

Opioid-Based Haptens: Development of Immunotherapy

Over the past decades, extensive preclinical research has been conducted to develop vaccinations to protect against substance use disorder caused by opioids, nicotine, cocaine, and designer drugs. Morphine or fentanyl derivatives are small molecules, and these compounds are not immunogenic, but when conjugated as haptens to a carrier protein will elicit the production of antibodies capable of reacting specifically with the unconjugated hapten or its parent compound. The position of the attachment in opioid haptens to the carrier protein will influence the specificity of the antiserum produced in immunized animals with the hapten-carrier conjugate. Immunoassays for the determination of opioid drugs are based on the ability of drugs to inhibit the reaction between drug-specific antibodies and the corresponding drug-carrier conjugate or the corresponding labelled hapten. Pharmacological studies of the hapten-carrier conjugates resulted in the development of vaccines for treating opioid use disorders (OUDs). Immunotherapy for opioid addiction includes the induction of anti-drug vaccines which are composed of a hapten, a carrier protein, and adjuvants. In this review we survey the design of opioid haptens, the development of the opioid radioimmunoassay, and the results of immunotherapy for OUDs.

Optimization and analytical behavior of a morphine electrochemical sensor in environmental and biological samples based on graphite rod electrode using graphene/Co3O4 nanocomposite

In this research, a new sensor based on graphene/Co₃O₄ (Gr/Co₃O₄) nanocomposite was employed for electrochemically determination of morphine (MOR). The modifier was synthesized with a simple hydrothermal technique and well characterized using X-ray difraction (XRD), scanning electron microscope (SEM) and energy dispersive X-ray spectroscopy (EDS) tools. The modified graphite rod electrode (GRE) was revealed a high electrochemical catalytic activity for the MOR oxidation and employed for the electroanalysis of trace MOR concentration by means of differential pulse voltammetry (DPV) technique. At the optimum experimental factors, the resulting sensor offered a good response for MOR in the concentration range of 0.5-100.0 μM with a detection limit of 80 nM. In addition, the modified electrode demonstrated an acceptable selectivity, stability and reproducibility. This assay was also provided a valid platform for the detection of MOR in environmental and biological samples with acceptable recoveries and RSD in the range of 97.2-102.8% and 1.7-3.4%, respectively. Taking to the simplicity, low cost and short analysis time, this approach is suggested for clinical, environmental and forensic testing of MOR.

Progress in Immunoassays of Toxic Alkaloids in Plant-Derived Medicines: A Review

Plants are the cradle of the traditional medicine system, assuaging human or animal diseases, and promoting health for thousands of years. However, many plant-derived medicines contain toxic alkaloids of varying degrees of toxicity that pose a direct or indirect threat to human and animal health through accidental ingestion, misuse of plant materials, or through the food chain. Thus, rapid, easy, and sensitive methods are needed to effectively screen these toxic alkaloids to guarantee the safety of plant-derived medicines. Antibodies, due to their inherent specificity and high affinity, have been used as a variety of analytical tools and techniques. This review describes the antigen synthesis and antibody preparation of the common toxic alkaloids in plant-derived medicines and discusses the advances of antibody-based immunoassays in the screening and detection of toxic alkaloids in plants or other related matrices. Finally, the limitations and prospects of immunoassays for toxic alkaloids are discussed.

Quantitative detection of morphine based on an up-conversion luminescent system

An up-conversion luminescent material converts low-frequency excitation light into high-frequency emission light through photons and has the advantages of long fluorescence lifetime, narrow emission peak and low toxicity; thus, this material has many unique applications in the detection and identification of biomolecules. In this study, an ultrasensitive up-conversion luminescent system for the quantitative detection of morphine was developed. The principle of this system is based on infrared light as an excitation light source to convert light with lower energy into excitation light with higher energy. The up-conversion luminescent material is used as a label and through the processing and analysis of the excitation light intensity, the quantitative detection of morphine concentration is achieved. At the same time, the excitation light can avoid the interference and scattering phenomenon of the autofluorescence of the biological sample, which improves the system's detection sensitivity. An algorithm for light intensity processing is added to process image data, reduce the interference caused by noise during image acquisition and improve the accuracy of morphine detection. The T/C value is calculated to achieve the quantitative detection of morphine with a detection limit of 0.1 ng mg-1 and detection time within 0.5 min. The up-conversion luminescent system has the advantages of quantitative detection, convenience, portability, short detection time and low price. Thus, the system can be used for the detection of other biomolecules or for other applications such as food analysis, environmental detection, national security, etc.

Cobalt Oxide Nanoparticles/Graphene/Ionic Liquid Crystal Modified Carbon Paste Electrochemical Sensor for Ultra-sensitive Determination of a Narcotic Drug

Purpose: Drug-abuse, namely morphine (MO) affects the metabolism of neurotransmitters such as dopamine (DA). Therefore, it is crucial to devise a sensitive sensing technique to simultaneously determine both compounds in real samples. Methods: The fabrication of the sensor is based on in situ modification of a carbon paste (CP) electrode with cobalt oxide nanoparticles, graphene, and ionic liquid crystal in presence of sodium dodecyl sulfate; CoGILCCP-SDS. The modified sensor is characterized using scanning electron microscopy, electrochemical impedance spectroscopy and voltammetry measurements. Results: Electron transfer kinetics and analytical performance of the proposed sensor were enhanced due to the synergistic role of all the modifiers. The simultaneous determination of MO and DA achieved low detection limits of 0.54 nmol L-1 and 0.25 nmol L-1, respectively. Besides, a carbon-based electrochemical sensor is fabricated for the nano-molar determination of MO in real samples and formulations. The sensor showed fouling resistance and anti-interference ability in presence of other species in human fluids. The real sample analysis of MO was successfully achieved with good recovery results in urine samples and pharmaceutical tablets. Linear dynamic range, sensitivity, detection limit and quantification limit of MO in urine were 5 nmol L-1 to 0.6 μmol L-1, 6.19 μA/μmol L-1, 0.484 nmol L-1 and 1.61 nmol L-1, respectively. Conclusion: This sensor has great ability to be extended for electrochemical applications in assaying of many drugs.

Sensitivity Enhancement for Direct Injection Capillary Electrophoresis to Determine Morphine in Human Serum via In-capillary Derivatization

Rapid and simple micellar electrokinetic chromatography (MEKC) with in-capillary derivatization and fluorescence detection has been developed to determine morphine in human serum. The sample was introduced into a background electrolyte (BGE) containing potassium ferricyanide, whereas morphine was oxidized into highly fluorescent product, pseudomorphine. Different parameters for derivatization and subsequent separation were systematically investigated for the analysis of morphine in serum. Efficient performance of the developed MEKC system was carried out in a single run using BGE made up of 70 mM sodium tetraborate decahydrate (pH 10.5), 0.30 mM potassium ferrricyanide, 80 mM sodium dodecyl sulfate, and applied voltage of 9 kV. The combination of MEKC with in-capillary derivatization of morphine was successfully achieved with a high degree of sensitivity. The validation of the method showed good linearity between areas of morphine and the corresponding concentrations over the range of 5-5000 ng/mL. Excellent accuracy and precision were obtained at all concentration levels. The mean recoveries of morphine were ranging from 83.86 to 94.45%. The validated MEKC method successfully permitted determination of morphine in clinical samples after a single oral dose of controlled release morphine sulfate tablets.

A new platform for sensing urinary morphine based on carrier assisted electromembrane extraction followed by adsorptive stripping voltammetric detection on screen-printed electrode

Electromembrane extraction (EME) coupled with electrochemical detection on screen-printed carbon electrode has been developed for the quantification of morphine in urine samples. Charged morphine molecules were extracted from an aqueous sample by applying an electrical potential through a thin supported liquid membrane (SLM) into an acidic aqueous acceptor solution (20 µL) placed inside the lumen of a hollow fiber. Then, the acceptor solution was mixed with 20 µL of NaOH solution (0.1 M) and analyzed using screen printed electrochemical strip. Differential pulse voltammetry (DPV) peak current at 0.18 V was selected as the signal and the influences of experimental parameters were investigated and optimized using Box-behnken design and also one-variable-at-a-time methodology as follows: adsorptive accumulation time, 40 s; SLM, 2-nitrophenyl octyl ether+10% tris-(2-ethylhexyl) phosphate+10% di-(2-ethylhexyl) phosphate; pH of the sample solution, 6.0; pH of the acceptor solution, 1.0; EME time, 24 min; EME potential, 90 V and stirring rate, 1000 rpm. The calibration curve which was plotted by the variation of DPV currents as a function of morphine concentration was linear within the range of 0.005-2.0 µg mL(-1). The limit of detection and the limit of quantification were 0.0015 (S/N=3) and 0.005 µg mL(-1), respectively. Finally, the proposed method was able to determine morphine simply and effectively at concentration levels encountered in toxicology and doping.

Determination of morphine at gold nanoparticles/Nafion® carbon paste modified sensor electrode

A novel and effective electrochemical sensor for the determination of morphine (MO) in 0.04 mol L(-1) universal buffer solution (pH 7.4) is introduced using gold nanoparticles electrodeposited on a Nafion modified carbon paste electrode. The effect of various experimental parameters including pH, scan rate and accumulation time on the voltammetric response of MO was investigated. At the optimum conditions, the concentration of MO was determined using differential pulse voltammetry (DPV) in a linear range of 2.0 × 10(-7) to 2.6 × 10(-4) mol L(-1) with a correlation coefficient of 0.999, and a detection limit of 13.3 × 10(-10) mol L(-1), respectively. The effect of common interferences on the current response of morphine namely ascorbic acid (AA) and uric acid (UA) is studied. The modified electrode can be used for the determination of MO spiked into urine samples, and excellent recovery results were obtained.

Determining plasma morphine levels using GC-MS after solid phase extraction to monitor drug levels in the postoperative period

OBJECTIVE

To implement a selective and sensitive analytical method to quantify morphine in small volumes of plasma by gas-liquid chromatography-mass spectrometry (GC-MS), aimed at post-operatively monitoring the drug.

METHOD

A gas-liquid chromatographic method with mass detection has been developed to determine morphine concentration in plasma after solid phase extraction. Morphine-d3 was used as an internal standard. Only 0.5 mL of plasma is required for the drug solid-phase extraction in the Bond Elut-Certify, followed by the quantification of morphine derivative by GC-MS using a linear temperature program, a capillary fused silica column, and helium as the carrier and make-up gas. The method was applied to determine morphine content in plasma samples of four patients during the postoperative period of cardiac surgery. Patient-controlled analgesia with morphine was performed by a venous catheter, and a series of venous blood samples were collected. After the oro-After the orotracheal extubation, morphine plasma levels were monitored for up to 36 hours.

RESULTS

The run time was 16 minutes because morphine and the internal standard were eluted after 8.8 minutes. The GC-MS method had 0.5 -1000 ng/mL linearity range (r(2)=0.9995), 0.1 ng/mL limit of detection, intraday and interday precision equivalent to 1.9% and 6.8%, and 0.1% and 0.8% systematic error (intraday and interday, respectively). The analytical method showed optimal absolute (98%) and relative (100.7%) recoveries. Morphine dose requirements and plasma levels are discussed.

CONCLUSION

The analytical gas-liquid chromatography-mass spectrometry method is selective and adequate for morphine measurements in plasma for applications in clinical studies.

Morphine and its metabolites: Analytical methodologies for its determination

The present article reviews the methods of determination published for morphine and its metabolites covering the period from 1980 until at the first part of 2006. The overview includes the most relevant analytical determinations classified in the following two types: (1) non-chromatographic methods and (2) chromatographic methods.

Development and validation of a radioreceptor assay for the determination of morphine and its active metabolites in serum

This article describes the development and validation of a radioreceptor assay for the determination of morphine and morphine-6-beta-glucuronide (M6G) in serum. The assay is based on competitive inhibition of the mu-opioid-selective radiolabeled ligand [3H]-DAMGO by opioid ligands (e.g. M6G) for binding to the striatal opioid receptor. The assay has been validated according to the Washington Conference Report on Analytical Method Validation. The radioreceptor assay can be performed in serum without prior pre-treatment of the sample. Direct addition of the sample results in no significant loss in maximal binding sites, and therefore, no loss in sensitivity. The assay proves to be selective for a multitude of opioid agonists and antagonists (e.g. morphine IC50 = 4.1 nM and M6G IC50 = 12.8 nM). Moreover, morphine-3-glucuronide (M3G) displays a low affinity (IC50 = 1100 nM) for the mu-opioid receptor and according to the literature demonstrates no analgesic activity. This makes discrimination, in relation to the analgesic effect, of the two metabolites of morphine possible. The assay is fast (assay time <4h, analysis 5 min/sample), easy and the sensitivity (limit of detection (LOD) = 1.6 nM M6G-equivalents) is such that very potent agonists, like morphine and M6G, can be measured at the desired serum levels. The assay is accurate (<18%), but precision is limited if measured over several days (>35%). The assay is most accurate and precise if measured over a range from 3.5 to 40 nM M6G-equivalents. Based on the limited inter-assay precision, we propose to use this receptor assay mainly as a screening tool for neonates treated with morphine.

High-performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites by two-step solid-phase extraction

To provide more accurate measurement of morphine and its metabolites for a study of the genetic differences on morphine response, a method for the analysis of morphine and its metabolites is described which has the advantages of increased sensitivity and specificity by using a cleaner extraction. The new extraction method involves both the hydrophobic isolation on a carbon cartridge and ion-exchange isolation on ion-exchange resin which has not preliminary been described for morphine analysis. The combination of these two steps successfully purified drugs from human plasma with maximum removal of interfering substance comparing with a conventional C18 cartridge alone. The analytes are quantified by high-performance liquid chromatography on a reversed-phase C18 column employing a mobile phase consisting of 25% acetonitrile in 0.05 M phosphate buffer (pH 2.1), and 2.5 mM sodium dodecyl sulfate as the pairing ion with a combination of electrochemical and fluorometric detections. The recoveries for morphine (M), morphine-3-glucuronide (M3G), morphine-6-glucuronide (M6G) and hydromorphone after the SPE procedure were 86+/-7.1%, 82+/-6.9%, 79+/-6.0% and 85+/-6.0%, respectively. Limits of detection for this method are 0.1 ng/ml for M, and 0.18 ng/ml for M3G and M6G. Limits of quantitation were approximately 0.25 ng/ml for M, and 0.45 ng/ml for M3G and M6G. The present assay was applied to measure M, M3G and M6G content in human plasma to test the applicability and suitability of this method for clinical and research use.

Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children

AIMS

To measure morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children following a single intravenous dose of morphine.

METHODS

Twenty-nine paired samples of cerebrospinal fluid and plasma were collected from children with leukaemia undergoing therapeutic lumbar puncture. An intravenous dose of morphine was administered at selected intervals before the procedure. Concentrations of morphine and morphine-6-glucuronide (M6G) were measured in each sample. Morphine was measured using a specific radioimmunoassay (r.i.a.) and M6G was measured using a novel enzyme-linked immunosorbent assay (ELISA).

RESULTS

The ELISA for measuring M6G was highly sensitive. The intra-and interassay variations were less than 15%. Using a two-compartment model for plasma morphine, the area under the curve to infinity (AUC, 7143 ng ml-1 min), volume of distribution (3.6 l kg-1 ) and elimination half-life (88 min) were comparable with those reported in adults. Clearance (35 ml min-1 ) was higher than that in adults. Morphine-6-glucuronide was readily synthesized by the children in this study. The elimination half-life (321 min) and AUC (35507 ng ml-1 min) of plasma M6G were much greater than those of morphine.

CONCLUSIONS

Extensive metabolism of morphine to M6G in children with cancer has been demonstrated. These data provide further evidence to support the importance of M6G accumulation after multiple doses. There was no evidence that morphine passed more easily into the CSF of children than adults.

Determination of drugs of abuse in blood

The detection and quantitation of drugs of abuse in blood is of growing interest in forensic and clinical toxicology. With the development of highly sensitive chromatographic methods, such as high-performance liquid chromatography (HPLC) with sensitive detectors and gas chromatography-mass spectrometry (GC-MS), more and more substances can be determined in blood. This review includes methods for the determination of the most commonly occurring illicit drugs and their metabolites, which are important for the assessment of drug abuse: Methamphetamine, amphetamine, 3,4-methylenedioxymethamphetamine (MDMA), N-ethyl-3,4-methylenedioxyamphetamine (MDEA), 3,4-methylenedioxy-amphetamine (MDA), cannabinoids (delta-9-tetrahydrocannabinol, 11-hydroxy-delta-9-tetrahydrocannabinol, 11-nor-9-carboxy-delta-9-tetrahydrocannabinol), cocaine, benzoylecgonine, ecgonine methyl ester, cocaethylene and the opiates (heroin, 6-monoacetylmorphine, morphine, codeine and dihydrocodeine). A number of drugs/drug metabolites that are structurally close to these substances are included in the tables. Basic information about the biosample assayed, work-up, GC column or LC column and mobile phase, detection mode, reference data and validation data of each procedure is summarized in the tables. Examples of typical applications are presented.

Determination of morphine in urine by solid-phase immunoextraction and high-performance liquid chromatography with electrochemical detection

The analysis of morphine in biological fluids is of vital interest in monitoring opiate abuse and in drug abuse research. Although methods for analysis of morphine and its metabolites are well established, studies are still being carried out to improve sample preparation procedures as well as detection levels of morphine in biological samples. In this study, morphine-specific immunosorbents were developed to concentrate morphine prior to HPLC analysis. Urine (0.1 ml) was diluted 10-fold with phosphate-buffered saline, pH 7.4 (PBS), loaded onto a solid-phase immunoextraction column and washed with 15 ml PBS followed by elution with 2 ml of elution buffer (40% ethanol in PBS, pH 4). The eluted fraction was analysed for morphine by HPLC-electrochemical detection using a cyanopropyl (CN) analytical column with 25% acetonitrile in phosphate buffer-sodium lauryl sulphate, pH 2.4 as the mobile phase. Duration of the extraction procedure was approximately 40 min. Calibration graphs were linear from 100 ng ml-1 to 500 ng ml-1 in urine. The inter-assay R.S.D. was < 10% and the recovery of morphine from urine was > 98%. Immunocolumns demonstrated remarkably high specificity towards morphine showing minimal binding with other opiate metabolites such as codeine, normorphine, norcodeine, morphine-3-glucuronide, morphine-6-glucuronide.

High-performance liquid chromatography-mass spectrometry-mass spectrometry analysis of morphine and morphine metabolites and its application to a pharmacokinetic study in male Sprague-Dawley rats

A high-performance liquid chromatography tandem mass spectrometry-mass spectrometry (LC-MS-MS) assay was developed for the analyses of morphine, morphine glucuronides and normorphine in plasma samples from rats. The analytes were extracted by using C2 solid-phase extraction cartridges. The extraction recoveries were 100% for morphine, 84% for morphine-3-glucuronide, 64% for morphine-6-glucuronide and 88% for normorphine. Both intra- and inter-assay variabilities were below 11%. Using a plasma sample size of 100 microliters, the limits of detection were 13 nmol l-1 (3.8 ng ml-1) for morphine, 12 nmol l-1 (5.5 ng ml-1) for morphine-3-glucuronide, 26 nmol l-1 (12 ng ml-1) for morphine-6-glucuronide and 18 nmol l-1 (5.0 ng ml-1) for normorphine, at a signal-to-noise ratio of 3. The present assay was applied to a pharmacokinetic study in rats after intraperitoneal administration of morphine.

Development of highly sensitive and specific HPLC assay for plasma morphine using direct injection technique and post-column derivatization

An extremely simple, rapid and reproducible analytical method was developed for the determination of morphine in human plasma using a high performance liquid chromatography utilizing a column-switching technique and protein-coated precolumn. Morphine from plasma (500 microL) was preconcentrated on the protein-coated pre-column without sample pre-treatment. This column acted at the same time as a clean up device. The drug was transferred on-line to the analytical column followed by post-chromatographic derivatization and fluorimetric detection. Post-column derivatization was based on the oxidative dimerization of morphine to fluorescent pseudomorphine by potassium hexacyanoferrate (III). The average morphine recoveries over a concentration range of 10 to 100 ng/mL ranged from 94.84 to 100.70%, and relative standard deviations ranged from 1.36 to 2.13%.

Determination of phase II drug metabolites in equine urine by micellar electrokinetic capillary chromatography

Micellar electrokinetic capillary chromatography (MECC) using diode array detection has been investigated for the determination of phase I and phase II metabolites of drugs in biofluids. Methods were optimised for the determination of morphine, morphine-3-glucuronide, morphine-6-glucuronide, normorphine, meclofenamic acid and its metabolites in equine urine. Solid-phase extraction procedure were developed to concentrate and purify the analytes from spiked and post administration urines for MECC analysis. A simple on-line procedure for monitoring the kinetics of hydrolysis of morphine-glucuronide conjugates by beta-glucuronidase was demonstrated.

A specific radioimmunoassay for the determination of morphine-6-glucuronide in human plasma

A specific antiserum for morphine-6-glucuronide (M6G) has been raised in a rabbit in response to immunization with a novel hapten:protein conjugate (N-aminobutylnormorphine-6-glucuronide-thyroglobulin). Cross-reactivity with morphine and structurally related compounds was found to be negligible as expected from the nature of this immunogen. Using this antiserum, a simple, rapid and robust radioimmunoassay (RIA) has been developed for determination of M6G in samples of human plasma. The assay has a sensitivity of 0.05 ng/mL using 100 microL sample volumes and affords complete recovery of M6G over the range 2-200 ng/mL. The presence of morphine or morphine-3-glucuronide at concentrations up to 100 times the levels of M6G did not result in any measurable interference. Close agreement was obtained between M6G results obtained using the RIA and a specific high-performance liquid chromatography assay. This RIA offers an attractive alternative to existing methods for the determination of M6G in human plasma and will facilitate further metabolic and pharmacokinetic studies of morphine and M6G in the clinical setting.

Analysis of unconjugated morphine, codeine, normorphine and morphine as glucuronides in small volumes of plasma from children

A sensitive method for the analysis of unconjugated morphine, codeine, normorphine and total morphine after hydrolysis of glucuronide conjugates is described. The method was applicable to 50-microliters volumes of plasma. The analytes were converted to heptafluorobutyryl (HFB) derivatives before analysis by gas chromatography-negative ion chemical ionization mass spectrometry. Morphine and codeine were quantified against their [2H3]-isotopomers. Linearity, precision and accuracy were quite acceptable (in the 10(-10)-10(-9) g range), and the absolute limits of detection were < 1 pg.